GeneHealth - Your precision medicine

Oligodendroglioma

Disease Details

Family Health Simplified

Buy Membership

Description: Oligodendroglioma is a type of brain tumor that originates from the oligodendrocytes, the cells that create the myelin sheath around nerve fibers in the central nervous system.
Type: Oligodendroglioma is a type of primary brain tumor that originates from oligodendrocytes, which are cells that produce the myelin sheath covering nerve fibers. It is generally classified as a glioma. Oligodendrogliomas are not typically inherited in a traditional Mendelian fashion. Most cases occur sporadically, meaning they are not passed down from parent to child through genetic transmission. However, there are certain genetic mutations, such as in the IDH1, IDH2, and chromosome 1p/19q co-deletion, that are commonly associated with these tumors.
Signs And Symptoms: Oligodendroglioma arise mainly in the frontal lobe and in 50–80% of cases, the first symptom is the onset of seizure activity, without having any symptoms beforehand. Headaches combined with increased intracranial pressure are also a common symptom of oligodendroglioma. Depending on the location of the tumor, many different neurological and neuropsychological deficits can be induced, including, but not limited to, visual loss, motor weakness, cognitive decline, and anxiety. A computed tomography (CT) or magnetic resonance imaging (MRI) scan is necessary to characterize tumor size, location, and hetero- or homogeneity. Final diagnosis relies on biopsy and histopathologic examination of the tumor mass.
Prognosis: Oligodendrogliomas, like all other infiltrating gliomas, have a very high (almost uniform) rate of recurrence and gradually increase in grade over time. Recurrent tumors are generally treated with more aggressive chemotherapy and radiation therapy. Recently, stereotactic surgery has proven successful in treating small tumors that have been diagnosed early.
Long-term survival is reported in a minority of patients. With aggressive treatment and close monitoring, it is possible to outlive the typical life expectancies for low grade oligodendroglioma. Westergaard's study (1997) showed that patients younger than 20 years had a median survival of 17.5 years. For patients that are over 30, the survival rate is lower but as treatment options grow, the survival rate is higher. However, a patient with bad general health is more likely to die sooner than those that have good general health. Another study shows a 34% survival rate after 20 years. However, as discussed above, such figures can be misleading since they do not factor in the types of treatment nor the genetic signature of the tumors. Additionally, such historic data loses significance due to the relatively long survival of patients (compared to other types of brain tumors) and the introduction of newer treatment options over time.
Onset: Oligodendroglioma is a type of brain tumor that originates from oligodendrocytes, which are cells that produce the myelin sheath covering nerve cells.

### Onset
- **Age Range**: Typically occurs in adults between the ages of 30 and 50, but it can also be found in children.
- **Symptoms**: Gradual in onset; may include seizures, headaches, and neurological deficits depending on the tumor's location in the brain. Other possible symptoms are changes in personality or memory loss.

### Non-Applicable (NaN) Information
- **Exact Cause**: The exact cause remains unknown. However, genetic mutations such as those in the IDH1, IDH2, and 1p/19q co-deletion are commonly associated with oligodendrogliomas.
- **Preventive Measures**: There are no specific preventive measures due to the unclear etiology. Regular medical check-ups and awareness of symptoms can help in early detection and management.
Prevalence: Oligodendroglioma is a relatively rare type of brain tumor, accounting for approximately 2-5% of all primary brain tumors and around 10-15% of gliomas. While the exact prevalence can vary by population and study, these tumors tend to present more frequently in adults aged between 35 and 44 years and have a slight male predominance.
Epidemiology: Oligodendroglioma is a type of glioma that arises from oligodendrocytes, which are cells that produce the myelin sheath covering nerve cells in the brain.

### Epidemiology:
- **Incidence**: Oligodendrogliomas are relatively rare, accounting for about 2-5% of all primary brain tumors and approximately 10-15% of gliomas.
- **Age**: They are most commonly diagnosed in adults between the ages of 35 and 50.
- **Gender**: There is a slight male predominance in the incidence of oligodendrogliomas, with a male-to-female ratio of approximately 1.3:1.
- **Geographic Variation**: The incidence can vary by geographic region, with certain areas reporting higher or lower frequencies, but specific reasons for these variations are not well understood.
Intractability: Oligodendroglioma, a type of brain tumor arising from oligodendrocytes, can vary in its level of intractability. Treatment outcomes depend on factors such as the tumor's grade, location, and response to therapy. While low-grade oligodendrogliomas may be more manageable and responsive to treatment, high-grade or recurrent forms can be more challenging to treat effectively. Advances in surgical techniques, radiation therapy, and chemotherapy have improved prospects, but some cases remain difficult to completely resolve.
Disease Severity: Oligodendroglioma is a type of brain tumor originating from oligodendrocytes, which are cells in the brain and spinal cord that produce myelin. The severity of oligodendrogliomas can vary. They are generally divided into two grades:

1. **Grade II (low-grade) oligodendrogliomas**: These grow slowly and may be less aggressive, but still require treatment and monitoring as they can progress over time.

2. **Grade III (anaplastic) oligodendrogliomas**: These are more aggressive and grow more quickly, often requiring more intensive treatment.

The prognosis and treatment plan depends on various factors including the tumor grade, location, and genetic markers.
Healthcare Professionals: Disease Ontology ID - DOID:3181
Pathophysiology: Oligodendroglioma is a type of glioma that arises from oligodendrocytes, which are cells in the brain and spinal cord that produce myelin, the substance that insulates nerve fibers. The exact pathophysiology involves several genetic mutations, notably in the isocitrate dehydrogenase (IDH) genes, as well as co-deletion of chromosome arms 1p and 19q. These genetic alterations lead to abnormal cell growth and proliferation, resulting in the formation of a tumor. Oligodendrogliomas typically grow more slowly than other gliomas but can still infiltrate adjacent brain tissue and cause neurological symptoms depending on their location and size.
Carrier Status: Oligodendroglioma is a type of primary brain tumor that arises from oligodendrocytes, which are cells responsible for creating the myelin sheath around nerve fibers in the central nervous system. The concept of "carrier status" does not typically apply to oligodendroglioma, as it is not generally considered a hereditary cancer. Instead, it usually occurs sporadically. Although genetic mutations (such as the co-deletion of chromosome arms 1p and 19q) are associated with the tumor, these are somatic mutations occurring in the tumor cells and not in the germline cells that would be passed down to offspring.
Mechanism: Oligodendroglioma is a type of brain tumor derived from oligodendrocytes, which are cells in the central nervous system that produce myelin. The mechanism of oligodendroglioma involves the abnormal growth and division of these glial cells.

### Molecular Mechanisms
1. **Chromosomal Co-deletion:** One of the hallmark molecular features of oligodendrogliomas is the co-deletion of chromosomal arms 1p and 19q. This genetic alteration is associated with better response to therapy and a more favorable prognosis.

2. **IDH1 and IDH2 Mutations:** Mutations in the isocitrate dehydrogenase genes (IDH1 and IDH2) are common in oligodendrogliomas. These mutations result in the production of an oncometabolite called 2-hydroxyglutarate, which can interfere with cellular metabolism and epigenetic regulation.

3. **TERT Promoter Mutations:** Mutations in the TERT promoter region, which enhances the expression of telomerase reverse transcriptase, lead to increased telomerase activity, providing the tumor cells with the capability to maintain telomere length and continue dividing.

4. **CIC and FUBP1 Mutations:** Mutations in CIC (Capicua Transcriptional Repressor) and FUBP1 (Far Upstream Element Binding Protein 1) are also frequently observed. These genetic changes may contribute to tumorigenesis by deregulating pathways involved in cell growth and differentiation.

Understanding these molecular mechanisms aids in the diagnosis, treatment planning, and prognostication of oligodendrogliomas.
Treatment: Oligodendrogliomas are generally considered to be incurable using current treatments. However compared to the more common astrocytomas, they are slowly growing with prolonged survival. In one series, median survival times for oligodendrogliomas were 11.6 years for grade II.However, such figures can be misleading since they do not factor in the types of treatment nor the genetic signature of the tumors. A recent study analyzed survival based on chromosomal deletions and the effects of radiation or chemotherapy as treatment, with the following results (both low-grade and anaplastic oligodendrogliomas): 1p/19q deletion with radiation = 121 months (mean), 1p/19q deletion with chemotherapy = over 160 months (mean not yet reached), no 1p/19q deletion with radiation = 58 months (mean), and no 1p/19q deletion with chemotherapy = 75 months (mean).Given the indolent nature of this tumor and the potential morbidity associated with neurosurgery, chemotherapy and radiation therapy, most neurooncologists will initially pursue a course of watchful waiting and treat patients symptomatically. Symptomatic treatment often includes the use of anticonvulsants for seizures and steroids for brain swelling.
The standard dosing schedule of temozolomide is five consecutive days of daily dosing during 28-day cycles. However, different dosing schedules may produce better results, such as continuous daily dosing using lower amounts of drug (e.g. 21-day dosing during 28-day cycles). As an example of an altered dosing schedule, promising results have been shown using lower daily doses on each day for 7 weeks, followed by a 4-week off periods. Regarding the duration of dosing, for oligodendrogliomas the duration prescribed by oncologists varies considerably ranging from 6 cycles to over 32 cycles (i.e. over three years). In one study, researchers compared patients who received temozolomide for at least 12 months on the 5/28 day cycle, dividing such patients into two groups: "short term" patients receiving temozolomide for 12–18 cycles and those "long term" patients receiving 19 or more cycles (range was 19 to 32 cycles). Researchers found that there was a statistically significant advantage for "long term" treatment (median progression free survival for "short term" patients was 95 weeks (follow-up of 73 weeks), but for "long term" patients the median progression free survival was not yet reached (follow-up of 134 weeks)).Due to the diffusely infiltrating nature, oligodendrogliomas cannot be completely resected and are not curable by surgical excision. If the tumor mass compresses adjacent brain structures, neurosurgeons typically remove as much of the tumor as possible without damaging other critical, healthy brain structures. Surgery may be followed up by chemotherapy, radiation, or a mix of both, however recent studies suggest that radiation does not improve overall survival (even when age, clinical data, histological grading, and type of surgery are considered).
Compassionate Use Treatment: Oligodendroglioma, a type of brain tumor, may necessitate treatment approaches when standard options are insufficient. Here are some details related to compassionate use treatment and off-label or experimental treatments:

1. **Compassionate Use Treatment**:
- **Temozolomide**: Some patients may access this chemotherapy drug when other treatments fail, though it's generally approved for certain brain tumors.
- **Bevacizumab**: An anti-angiogenic drug that can be considered under compassionate use for reducing tumor growth by inhibiting blood vessel formation.

2. **Off-label or Experimental Treatments**:
- **Nivolumab (Opdivo)**: Although primarily approved for other cancers, it's being explored for use in oligodendrogliomas in clinical trials.
- **Lomustine (CCNU)**: Often used in combination with other therapies, this alkylating agent can be used off-label.
- **Clinical Trials**: Patients might consider enrolling in clinical trials, which offer access to experimental drugs like peptide vaccines, new targeted therapies, or CAR-T cell treatments.
- **Electric Field Therapy (Optune)**: Initially approved for glioblastoma, it’s being investigated for potential efficacy in treating oligodendroglioma.

Physicians and patients usually discuss these options based on individual case specifics, weighing potential benefits against risks.
Lifestyle Recommendations: Oligodendroglioma is a type of brain tumor that originates from oligodendrocytes, which are cells in the central nervous system. Specific lifestyle recommendations for managing oligodendroglioma include:

1. **Regular Check-Ups:** Maintain regular appointments with your healthcare team to monitor the tumor and manage any symptoms or side effects from treatments.
2. **Balanced Diet:** Consume a nutritious diet rich in fruits, vegetables, whole grains, and lean proteins to support overall health and recovery.
3. **Physical Activity:** Engage in regular, moderate exercise as tolerated, which can improve physical function, mood, and overall well-being.
4. **Rest and Recovery:** Ensure adequate rest and sleep to help the body recover from treatments and manage fatigue.
5. **Stress Management:** Practice stress-reducing techniques such as meditation, yoga, deep-breathing exercises, or mindfulness to support mental and emotional health.
6. **Avoid Toxins:** Limit exposure to environmental toxins, and avoid smoking and excessive alcohol consumption, as these can negatively impact overall health.
7. **Support Systems:** Build a strong support network of family, friends, or support groups to provide emotional and practical support.

Always consult with your healthcare provider before making any significant lifestyle changes.
Medication: Oligodendroglioma is a type of brain tumor arising from oligodendrocytes. Treatment for oligodendroglioma typically involves a combination of surgery, radiation therapy, and chemotherapy. Common chemotherapy medications used include:

1. **Temozolomide (TMZ)**: An oral chemotherapy drug often used due to its efficacy and ability to cross the blood-brain barrier.
2. **Procarbazine, Lomustine (CCNU), and Vincristine (PCV) regimen**: A combination of these drugs is frequently used, especially for anaplastic oligodendroglioma.

These treatments aim to target and reduce tumor growth, manage symptoms, and improve overall patient outcomes.
Repurposable Drugs: For oligodendroglioma, some repurposable drugs include:

1. **Temozolomide**: Originally developed for melanoma, temozolomide is an oral chemotherapy drug used to treat oligodendroglioma due to its ability to cross the blood-brain barrier.
2. **Procarbazine**: Initially used for Hodgkin's lymphoma, procarbazine is often part of PCV (procarbazine, lomustine, and vincristine) chemotherapy regimen for oligodendroglioma.
3. **Lomustine (CCNU)**: Originally intended for various cancers, lomustine is frequently used in combination therapies for recurrent or progressive oligodendroglioma.
4. **Vincristine**: A drug used primarily for leukemias and lymphomas, vincristine is included in the PCV regimen.

'NAN' does not correspond to any established medical terminology or conditions related specifically to oligodendroglioma. If you meant something else, please provide additional context.
Metabolites: For oligodendroglioma, certain metabolites may be altered and can be of diagnostic or prognostic importance. Some key metabolites include:

1. **N-acetylaspartate (NAA):** Typically decreased in oligodendrogliomas, reflecting neuronal loss or dysfunction.
2. **Choline:** Often increased due to its association with cell membrane turnover and tumor proliferation.
3. **Creatine:** May show variable changes, often evaluated in the context of energy metabolism.
4. **Lactate:** Can be elevated, indicating anaerobic metabolism within the tumor.

Magnetic Resonance Spectroscopy (MRS) is commonly used to assess these metabolite levels in vivo for diagnostic purposes.
Nutraceuticals: Oligodendroglioma is a type of brain tumor that arises from oligodendrocytes, cells that produce the myelin sheath covering nerve fibers. In terms of nutraceutical interventions, evidence is limited and they should never replace standard treatment options like surgery, radiation, and chemotherapy. Some potential nutraceuticals that have been explored for their general anti-cancer properties include:

1. Curcumin: Found in turmeric, it has anti-inflammatory and anti-cancer properties.
2. Resveratrol: A compound in red grapes that may inhibit cancer cell growth.
3. Green Tea Extract: Contains polyphenols which might have anti-tumor effects.

As for nanotechnology (nan.), it is an emerging field with potential applications in the treatment of oligodendroglioma, including:

1. Nanoparticle Drug Delivery: Nanoparticles can be designed to deliver chemotherapy agents directly to tumor cells, potentially reducing side effects.
2. Nanotheranostics: Combining therapy and diagnostics in one, this approach can help in targeted treatment and monitoring the effectiveness of the therapy.

Both nutraceuticals and nanotechnology warrant further research to determine their efficacy and safety in treating oligodendroglioma. Always consult healthcare providers for personalized medical advice.
Peptides: Oligodendrogliomas are a type of glioma, a primary brain tumor originating from oligodendrocytes. Among the various innovative treatment options being explored, two notable areas are peptides and nanotechnology.

**Peptides:**
Peptides are short chains of amino acids that can be designed to target specific molecules on the surface of cancer cells. In the context of oligodendrogliomas, peptide-based therapies can be used for precise targeting and delivery of therapeutic agents, potentially improving the effectiveness of treatment while minimizing damage to healthy tissues.

**Nanotechnology:**
Nanotechnology involves the use of nanoscale materials and devices for diagnosis and treatment. For oligodendrogliomas, nanoparticles can be engineered to deliver drugs specifically to tumor cells, increasing the concentration of the drug within the tumor while reducing systemic side effects. Nanoparticles can also be used to enhance imaging techniques, providing better visualization of the tumor.

Overall, both peptides and nanotechnology represent promising avenues for improving the treatment and management of oligodendrogliomas.